The current standard of care for breast cancer patients with severe menopausal symptoms calls for avoiding menopausal hormone therapy (MHT) based on concern about the possibility of estrogen stimulating tumor growth and cancer recurrence. But a comprehensive data review of evidence on the use of MHT published in the journal Menopause , suggests this standard may be too stringent and that patients should instead be counseled on whether these treatments could improve their quality of life, despite the risk.

“While recommending against the use of MHT after breast cancer is justified to reduce the risk of breast cancer relapse and death, it should be acknowledged that some patients may consider maintaining quality of life to be of equal or greater importance,” the researchers wrote.

For

See Full Page